Table I.
Patient data and therapeutic effects of kochi oxydol-radiation therapy for unresectable carcinomas.
| Hormone receptor | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pt. | Age, years | ER | PgR | HER2 | Treatment region (RT field) | Exposure dose, Gy | Evaluation method | FDG accumulation | Tumor size, mm | Therapeutic effect |
| 1 | 54 | (+) | (+) | (1+) | Left breast | X 44+E9 | PET-CT | 3.9→D | 14→D | CR |
| 2 | 67 | (+) | (+) | (−) | Right breast | X 44+E9 | PET-CT | 3.2→1.6 | 15→D | CR |
| 3 | 46 | (+) | (+) | (1+) | Left breast | X 44+E9 | PET-CT | No data→D | 10→D | CR |
| 4 | 70 | (+) | (+) | (−) | Right breast | X 44+E9 | PET-CT | No data→D | 7→D | CR |
| 5 | 48 | (+) | (+) | (1+) | Right breast | X 44+E9 | PET-CT | 5.4→D | 12→D | CR |
| 6 | 40 | (+) | (+) | (−) | Right breast | X 44+E9 | PET-CT | 2.7→D | 9→D | CR |
| 7 | 62 | (+) | (+) | (1+) | Right breast | X 44+E9 | PET-CT | No data | 11→D | CR |
| 8 | 63 | (+) | (+) | (1+) | Right breast | X 44+E9 | PET-CT | 1.9→1.0 | 15→D | CR |
| 9 | 76 | (+) | (+) | (−) | Left breast | X 44+E9 | PET-CT | No data→D | 7→D | CR |
| 10 | 43 | (+) | (+) | (1+) | Right breast | X 44+E9 | PET-CT | No data→D | 9→D | CR |
| 11 | 50 | (+) | (+) | (2+) | Right breast | X 44+E9 | PET-CT | 4.5→D | 20→D | CR |
| 12 | 60 | (−) | (−) | (2+) | Right breast | X 44+E9 | MRI | No data | 18→D | CR |
| 13 | 61 | (+) | (+) | (−) | Right breast | X 44+E9 | MRI | No data | 23→D | CR |
| 14 | 63 | (+) | (+) | (1+) | Right breast | X 44+E 9 | MRI | No data | 13→D | CR |
| 15 | 73 | (+) | (+) | (2+) | Left breast | X 44+E9 | PET-CT | 1.6→no data | 10→D | CR |
Pt., patient; RT field, radiation therapy field; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor type 2; CR, complete response; PR, partial response; PD, progressive disease; X, X-ray; E, Electron beam; D, disappearance; PET-CT, positron emission tomography-computed tomography; MRI, magnetic resonance imaging; Gy, gray.